Should My Startup Buy Or Produce The Proteins We Use?

By David Bienvenue

I joined Good Therapeutics (now Bonum Therapeutics) in the summer of 2021. This was a marvelous opportunity to develop a new class of regulated cytokine therapeutics for cancer and autoimmune diseases. My prime directive was to build a team focused on protein production and characterization, with an aim to select stable “manufacturable” leads to move into clinical development.